In chronic liver disease, hepatic stellate cell activation and degeneration of liver sinusoidal
endothelial cells lead to structural changes, which are secondary to fibrosis and the …

Background & Aims Non-invasive tests (NITs) for clinically significant portal hypertension
(CSPH; hepatic venous pressure gradient [HVPG]≥ 10 mmHg) have predominantly been …

Cirrhosis causes an increased resistance to portal blood flow. This increased resistance
results in an increase in portal pressure that subsequently activates several …

Background and Aims Risk stratification after cure from hepatitis C virus (HCV) infection
remains a clinical challenge. We investigated the predictive value of noninvasive surrogates …

Conclusions: Non-liver non-AIDS–related events were the leading causes of morbidity and
mortality after direct-acting antiviral cure among coinfected patients with advanced …

Background & Aims The latest Baveno VII consensus has provided guidance for identifying
patients who have truly recompensated from those with hepatic decompensation. This study …

Hepatitis C virus (HCV) cure after all-oral direct-acting antiviral (DAA) therapy greatly
improves the liver and immune system. We aimed to assess the impact of this HCV …

Background & Aims Spontaneous portosystemic shunts (SPSS) develop frequently in
cirrhosis. Changes over time and the effect of aetiological interventions on SPSS are …

Background It is unclear whether hepatocyte function and/or portal hypertension improves if
a sustained virologic response (SVR) is achieved with direct-acting antivirals in patients with …

Background Patients with a significant decrease in hepatic venous pressure gradient
(HVPG) have a considerable reduction of liver complications and higher survival after HCV …